Navicare Biotech Co (ROCO:8472) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:8472 Navicare Biotech Co Ltd ROCO:8472
60 GF Score
Price NT$76.00
GF Value NT$45.20
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Navicare Biotech Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Navicare Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$98.9 Mil. Navicare Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was NT$219.4 Mil. Navicare Biotech Co's annualized EBITDA for the quarter that ended in Jun. 2026 was NT$12.7 Mil. Navicare Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 25.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Navicare Biotech Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:8472' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.32   Med: 0   Max: 92.59
Current: 15.14

During the past 13 years, the highest Debt-to-EBITDA Ratio of Navicare Biotech Co was 92.59. The lowest was -5.32. And the median was 0.00.

ROCO:8472's Debt-to-EBITDA is ranked worse than
94.52% of 913 companies
in the Retail - Cyclical industry
Industry Median: 2.23 vs ROCO:8472: 15.14

Navicare Biotech Co  (ROCO:8472) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Navicare Biotech Co Debt-to-EBITDA Related Terms


Navicare Biotech Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Navicare Biotech Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navicare Biotech Co Debt-to-EBITDA Chart

Navicare Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Navicare Biotech Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ROCO:8472 vs AMZN, BABA, PDD: Debt-to-EBITDA Comparison

For the Internet Retail subindustry, Navicare Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navicare Biotech Co Debt-to-EBITDA vs Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Navicare Biotech Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Navicare Biotech Co's Debt-to-EBITDA falls into.


ROCO:8472
60GF Score
Navicare Biotech Co Ltd ROCO:8472
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Navicare Biotech Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Navicare Biotech Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(103.324 + 224.148) / 2.352
=139.23

Navicare Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(98.94 + 219.449) / 12.656
=25.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Navicare Biotech Co (ROCO:8472) Overvalued in 2026?

Based on GuruFocus' analysis, Navicare Biotech Co stock appears to be overvalued. The current stock price of NT$76.00 is trading 68.1% above its estimated GF Value™ of NT$45.20. GuruFocus considers Navicare Biotech Co to be Significantly Overvalued.

Key valuation signals for ROCO:8472:

  • Debt-to-EBITDA:
  • GF Value™: NT$45.20 vs. price of NT$76.00 (68.1% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the ROCO:8472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Navicare Biotech Co Business Description

Address No. 100, Section 4, Citizen Avenue, 4th Floor, Da-an District, Taipei, TWN
Gomaji Corp Ltd is a local e-commerce company. The company connects merchants to consumers by offering goods and services at a discount.
60GF Score

Get the complete analysis for ROCO:8472

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$76.00
Price
NT$45.20
GF Value